Advanced Filters
noise
Found 228 clinical trials
G Giovanna Vitichhi, MD

OnaBotulinumtoxin-A in Chronic Migraine Patients With Short or Long Disease History (the BACH Study)

The goal of this observational prospective multicentric study, 12 months duration is to investigate whether the history of Chronic Migraine and, more precisely, its duration for over or less than 10 years, can predict OBT-A treatment effectiveness. Since CM patients may have a complex psychopathological profile and psychiatric symptoms represent …

18 - 70 years of age All Phase N/A
H Håkon K Abildsnes, MD

A Pragmatic Trial of Machine Prescription for Migraine

The purpose of this study is to estimate the ability of ML models to predict the effect of migraine preventives. This will be achieved by first identifying sociodemographic, headache and comorbidity features of migraine patients. Headache days will then be measured for 4 weeks before starting a migraine preventive, and …

18 - 99 years of age All Phase N/A
M Marta Torres-Ferrús, PhD

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four …

18 - 45 years of age All Phase N/A
C Christian Woeber, Prof.

Closed-loop RTMS for Short-term Migraine Prevention

Migraine is a prevalent and debilitating primary headache disorder, where patients suffer from disabling symptoms that usually consist of a moderate to severe headache lasting 4 to 72 hours, nausea and/or vomiting, phonophobia and photophobia. Transcranial magnetic stimulation (TMS) is a noninvasive technique that is considered to be safe. Repetitive …

18 - 65 years of age All Phase N/A
P Pamela M Rist, ScD

Cocoa Extract for Migraine Trial

The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: Will we be able to enroll 114 participants during the recruitment period? Will participants take …

18 years of age All Phase N/A
J Jan-Erik Juto, PhD, MD

Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine

This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical stimulation (INMEST), as a preventative treatment for migraine. A total of 110 adults (18-65 years) with a history of migraine will be randomized …

18 - 65 years of age All Phase N/A
S Shengyuan Yu

Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.

18 - 75 years of age All Phase 2
A Alessandra Parisi, PHD

Neuropsychological Profile Characterization in Patients With Migraine: Cognitive Functioning and Psychological Variables

The overall objective is to define the neuropsychological profile of patients with migraine and evaluate its association with: psychological outcome measures (anxiety-depressive symptoms, pain catastrophizing, excessive worry, and coping strategies); the clinical profile of migraine; the prodromal, ictal, or interictal phase of the migraine attack; pharmacological therapy; and detoxification treatment …

18 - 65 years of age All Phase N/A
E Elisa Debien

Neuro-Complex & Multi Supplements for Migraine Prevention

The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of …

18 - 75 years of age All Phase N/A
M Michael R Leonard

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.

18 years of age All Phase 4

Simplify language using AI